Wealthcare Advisory Partners
CMPX icon

Wealthcare Advisory Partners’s Compass Therapeutics CMPX Stock Holding History

Wealthcare Advisory Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-60,962
Closed -$134K – 1117
2026
Q2 		$134K Buy
+60,962
New +$180K ﹤0.01% 1053

Other funds holding CMPX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Simplicity Wealth
Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return
Independent Financial Group
Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return

Wealthcare Advisory Partners's CMPX Position: Q3 2026 in Review

Wealthcare Advisory Partners sold out of Compass Therapeutics (CMPX) in Q3 2026, closing a stake of 60,962 shares — an estimated $134K sold.

Wealthcare Advisory Partners first reported a position in CMPX in Q2 2026 and held it in 1 quarter. The position peaked at $134K in Q2 2026. 33 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • Wealthcare Advisory Partners reported no remaining Compass Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 60,962 Compass Therapeutics shares in Q3 2026, an estimated $134K.
  • Wealthcare Advisory Partners first reported a position in Compass Therapeutics in Q2 2026 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Compass Therapeutics position peaked at $134K in Q2 2026.
  • 33 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2026, filed 21 Oct 2026.